Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain.

Ottoboni T, Quart B, Pawasauskas J, Dasta JF, Pollak RA, Viscusi ER.

Reg Anesth Pain Med. 2019 Dec 16. pii: rapm-2019-100714. doi: 10.1136/rapm-2019-100714. [Epub ahead of print]

PMID:
31843865
2.

Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial.

Pollak RA, Gottlieb IJ, Hakakian F, Zimmerman JC, McCallum SW, Mack RJ, Keller R, Freyer A, Du W.

Clin J Pain. 2018 Oct;34(10):918-926. doi: 10.1097/AJP.0000000000000609.

PMID:
29554032
3.

Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole

Pollak RA, Ilie C.

J Drugs Dermatol. 2017 Dec 1;16(12):1269-1273.

PMID:
29240863
4.

Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success.

Pollak RA, Siu WJJ, Tatsumi Y, Pillai R.

J Fungi (Basel). 2015 Jul 3;1(2):107-114. doi: 10.3390/jof1020107. Review.

5.

Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.

Elewski BE, Pollak RA, Pillai R, Olin JT.

J Drugs Dermatol. 2014 Nov;13(11):1394-8.

PMID:
25607708
6.

Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.

Pollak RA.

J Am Podiatr Med Assoc. 2014 Nov;104(6):568-73. doi: 10.7547/8750-7315-104.6.568. Review.

PMID:
25514267
7.

The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT.

J Drugs Dermatol. 2014 Sep;13(9):1124-32.

PMID:
25226015

Supplemental Content

Loading ...
Support Center